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Abstract
Aims/hypothesis Plasma soluble receptor for AGE (sRAGE)
may reflect the activity of the AGE–RAGE axis, which has
been proposed as a potential mechanism linking hyperglycae-
mia to vascular complications in diabetes. We have therefore
investigated: (1) whether sRAGE is associated with greater
prevalence of cardiovascular disease (CVD) andmicrovascular
complications in type 1 diabetic individuals; and (2) the extent
to which any such associations are explained by markers of
endothelial and renal dysfunction and inflammation.
Methods The study included 477 individuals (234 women;
mean age 42±10 [SD] years) from the EURODIAB
Prospective Complications Study. We used linear regression
analyses to investigate the differences in sRAGE levels
between individuals with and without vascular complica-
tions. All analyses were adjusted for age, sex, HbA1c,
duration of diabetes and other risk factors.
Results Individuals with CVD (n=116) had higher levels of
sRAGE than those without CVD or any microvascular
complications (n=178): β=0.15 (95% CI 0.04–0.27).
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Further adjustments for markers of endothelial (β=0.13
[0.02–0.24]) and renal dysfunction (β=0.10 [−0.01, 0.20])
and inflammation (β=0.12 [0.01–0.23]) attenuated these
differences; altogether these variables explained about 50%
of the association between sRAGE and prevalent CVD.
sRAGE levels tended to be higher in the presence and
across the levels of severity of albuminuria (p for trend=
0.087) and retinopathy (p for trend=0.057); adjustments for
endothelial and renal dysfunction and inflammation also
attenuated these differences.
Conclusions/interpretation sRAGE is associated with
greater prevalence of CVD in type 1 diabetic individuals,
and these associations may be partly explained by endo-
thelial and renal dysfunction and low-grade inflammation.
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esRAGE Endogenous secretory receptor for AGEs
IMT Intima–media thickness
RAGE Receptor for AGEs
sE-selectin Soluble E-selectin
sRAGE Soluble receptor for AGEs
sVCAM-1 Soluble vascular cell adhesion molecule-1
UAE Urinary albumin excretion rate
Introduction
The increased cardiovascular disease (CVD) risk in
individuals with diabetes mellitus cannot be fully explained
by traditional cardiovascular risk factors [1, 2]. Therefore,
other factors and mechanisms potentially involved need to
be explored. At the molecular level, one pathway through
which hyperglycaemia may lead to vascular complications
is the formation of AGEs. An important mechanism
through which AGEs induce vascular disease is by binding
to their specific receptors [3].
Several different receptors for AGEs have been identi-
fied, one of which is termed RAGE. Different cell types
including human endothelial cells express RAGE [4]. In
addition to cell-bound RAGE, soluble forms of RAGE
appear in the plasma [4, 5], as different splice variants of
RAGE (e.g. endogenous secretory receptor for AGE
[esRAGE]) leaking through the transmembrane and cyto-
solic domain [4, 6], and as a proteolytically cleaved form of
RAGE (sRAGE), which is most probably shed into the
circulation by the sheddase, known as a disintegrin and
metalloprotease 10 (ADAM 10) [7]. The functional role of
these soluble forms of RAGE in the circulation remains
unclear, but they may reflect the activity of the AGE–
RAGE axis. The ligation of RAGE activates the endothelial
cell and triggers multiple signalling cascades [8, 9],
resulting in activation and translocation of nuclear tran-
scription factors and transcription of the target genes,
including adhesion molecules [9, 10] and proinflammatory
cytokines [11]. The activation of RAGE may also lead to
nephropathy [12]. We have therefore hypothesised that the
activation of the AGE–RAGE axis may lead to vascular
complications in diabetes through increases in endothelial
and renal dysfunction and low-grade inflammation.
Evidence so far with regard to the association between
soluble forms of RAGE and vascular disease in diabetes is
contradictory, with several studies showing positive [13–
17], but also inverse associations [18, 19]. The fact that
these studies have investigated either esRAGE [18, 19] or
sRAGE [13–17] may explain the discrepancies. The few
studies that have examined both soluble forms of RAGE
have shown that sRAGE, but not esRAGE, is positively
associated with albuminuria in individuals with type 2
diabetes [16], whereas esRAGE and sRAGE were inversely
associated with intima–media thickness (IMT), a surrogate
marker of atherosclerosis [20] and its progression [21] in
individuals with type 1 diabetes. In addition, the extent to
which mechanisms such as endothelial and renal dysfunction
and low-grade inflammation, which are intertwined and
related to macro- and microvascular complications in diabetes
[22–24], underlie the association between sRAGE and
vascular complications (if any) has never been investigated.
In view of these considerations, we have investigated,
first, whether sRAGE levels are associated with a greater
prevalence of macro- and microvascular complications in
individuals with type 1 diabetes; and second, the extent to
which any such associations are explained (i.e. are
mediated) by markers of endothelial and renal dysfunction
and low-grade inflammation.
Methods
Participants and study design
We used data from the EURODIAB Prospective Complica-
tions Study, which is a follow-up of the EURODIAB IDDM
Complications Study that has been described in detail
elsewhere [25]. Briefly, baseline investigations were per-
formed between 1989 and 1991 on 3,250 individuals with
type 1 diabetes, defined as a clinical diagnosis made before
the age of 36 years, and needing continuous insulin therapy
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within 1 year of diagnosis. The individuals, aged between 15
and 60 years, were recruited from 31 centres in 16 European
countries. Sample selection was stratified by sex, age group
and duration of diabetes, to ensure sufficient representation
in all categories. All individuals gave informed consent and
the study was approved by the local Ethics Committees [25].
These individuals were invited for a follow-up examination
on average 7–9 years after the baseline examinations. Of the
3,250 included individuals, 1,880 (57.8%) returned for re-
examination [26–28]. At follow-up, a cross-sectional nested
case–control study of markers of inflammation and endothe-
lial dysfunction and their associations with complications
was performed in a subset of individuals (n=543) [22, 23,
29–33]. Cases were selected as those with a greatest vascular
complication burden as possible (n=348) and controls were
selected as those who were completely free of any
complications (i.e. with no evidence of CVD, albuminuria
and retinopathy) (n=195). This selection allowed us to
compare individuals with single or multiple complications
with individuals free of complications, according to the
study question, as efficiently as possible. Cases and controls
were unmatched, so that the impact of key variables, such as
age, could still be assessed and any adjustments were taken
care of in the analyses. The present study includes 477 of
these 543 individuals in whom complete data on serum
levels of sRAGE, endothelial and renal dysfunction markers,
inflammatory markers and other covariates were available.
The 66 individuals excluded only differed from the 477
included with regard to BP (higher systolic and diastolic
values; data not shown). Levels of sRAGE (as well as
AGEs, markers of inflammation and endothelial dysfunc-
tion) could not be determined at baseline because the blood
samples had run out.
Main determinant
Plasma levels of sRAGE were measured using a commer-
cially available ELISA kit (Quantikine; R&D systems,
Minneapolis, MN, USA) according to the manufacturer’s
protocol. Briefly, a monoclonal antibody generated against
the N-terminal extracellular domain of human RAGE was
used to capture sRAGE from plasma. Captured sRAGE was
detected with a polyclonal anti-human sRAGE antibody. After
washing, plates were incubated with streptavidin–horseradish
peroxidase, developed with appropriate substrate, and OD450
was determined using an ELISA plate reader. Measurements
were performed in duplicate and the intra-assay and inter-
assay CV values were 2.9% and 11.5%, respectively.
Main outcomes
Macrovascular disease CVD was defined as a positive
medical history of a cardiovascular event, including
myocardial infarction, angina, coronary artery bypass graft
and/or stroke, and/or ischaemic changes on a centrally
Minnesota-coded ECG [34].
Microvascular disease Albumin excretion rates (UAEs)
were measured from duplicate 24 h urine collections [27]
and micro- and macroalbuminuria were defined as a UAE
between 20 and 200, and above 200 μg/min, respectively.
We also calculated the estimated glomerular filtration rates
(eGFRs) for the individuals using the Cockcroft–Gault
formula [35]. Retinopathy was assessed from retinal photo-
graphs according to the EURODIAB protocol; non-prolif-
erative retinopathy was defined as the presence of one or
more microaneurysms, haemorrhages, and/or hard exu-
dates. Proliferative retinopathy was defined as any new
vessels, fibrous proliferations, pre-retinal haemorrhage,
vitreous haemorrhage or photocoagulation scars [36].
Other risk factors
BP was recorded twice with a random zero sphygmoma-
nometer (Hawskley, Lancing, UK). Hypertension was
defined as systolic pressure ≥140 mmHg, diastolic pressure
≥90 mmHg and/or use of antihypertensive drugs. Smoking
habits were ascertained by questionnaire and individuals
were categorised into categories: ‘non’, ‘moderate’ and
‘heavy smokers’, according to their levels of pack-years
smoked (none, and below or above the sex-specific median,
respectively). Weight and height were measured with
indoor clothing without shoes and BMI calculated. Blood
samples were taken, fasting if possible, for measurement of
lipids and glycaemic control. Cholesterol and triacylgly-
cerol levels were measured by enzymatic colorimetric tests
[37], and HDL-cholesterol was measured directly [38].
LDL-cholesterol was calculated from Friedewald’s formula
[39]. HbA1c was measured by a latex-enhanced turbidimet-
ric immunoassay (Roche Products, Welwyn Garden City,
UK). The reference range for this assay was 4.2–6.2%.
Potential mediators
Markers of endothelial dysfunction Soluble vascular cell
adhesion molecule-1 (sVCAM-1) and soluble E-selectin
(sE-selectin) were measured in duplicate by sandwich
enzyme immunoassays (R&D Systems, Oxford, UK). The
mean of the duplicates is presented. The intra- and inter-
assay CV values for sVCAM-1 were 4.0 and 9.1%,
respectively, and for sE-selectin, 2.1 and 3.1%, respectively.
Inflammatory markers Plasma levels of C-reactive protein
(CRP) were measured with a highly sensitive in-house
ELISA [23] and plasma levels of IL-6 and TNF-α were
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measured using commercially available ELISA kits (R&D
Systems) [23]. Intra- and inter-assay CV values were 3.9%
and 8.7%, 4.5% and 9.0%, and 7.3% and 8.5%, respectively.
AGEs Pentosidine levels were determined in unhydrolysed
urine [40]. Urinary excretion of pentosidine was normalised
for urine concentration by expressing it as nmol pentosi-
dine/mmol urinary creatinine. Protein-bound Nɛ-(carboxy-
methyl)lysine (CML) and Nɛ-(carboxyethyl)lysine (CEL)
were determined in plasma as previously described [41]
with an inter-assay CV of 6.0%. CML and CEL were
normalised for lysine concentration.
Statistical analyses
All analyses were performed with the Statistical Package
for Social Sciences (SPSS) version 15.0 for Windows
(SPSS, Chicago, IL, USA). Variables with a skewed
distribution (i.e. triacylglycerols, CRP, IL-6, TNF-α and
pentosidine) were loge transformed prior to further analy-
ses. Comparisons of characteristics between individuals
with or without vascular complications were performed
with Student’s t or χ2 tests, as appropriate. Cases were all
those individuals with CVD or retinopathy or micro- or
macroalbuminuria (n=299); controls were all those who
had no evidence of CVD, or retinopathy, and were
normoalbuminuric (n=178).
Linear regression analyses were used to examine
whether sRAGE levels differed between individuals with
or without CVD, and similarly, between those with or
without microvascular complications. In the analyses
comparing individuals with or without CVD, we excluded
those in whom CVD was absent but who did have any of
the other vascular complications (183 out of 361 individuals).
The same control group (n=178) was used in the analyses
comparing individuals with or without albuminuria and
individuals with or without retinopathy. These analyses were
first adjusted for age, sex, HbA1c and duration of diabetes,
and then further adjusted for other cardiovascular risk factors
(i.e. BMI, triacylglycerols, HDL- and LDL-cholesterol,
systolic BP and smoking). Linear regression analyses were
also used to examine the extent to which sRAGE levels were
associated with endothelial dysfunction (comprising an
averaged z score of sVCAM-1 and sE-selectin), inflamma-
tion (comprising an averaged z score of CRP, IL-6 and
TNF-α) and eGFR. Results of these analyses are expressed
in standardised regression coefficients (95% CIs) to allow
the comparison of the strength of the association between
sRAGE and each of these variables/scores. Finally, succes-
sive adjustments for these variables were performed in order
to investigate the extent to which these variables explained
(i.e. attenuated) the differences in sRAGE levels between
individuals with and without complications.
Because we measured the markers of the potential
mediators only once, the associations observed will tend
to be diluted. This is the reason why we combined the
markers per mechanism (i.e. inflammation and endothelial
dysfunction) to yield an inflammatory and an endothelial
dysfunction marker z score. We thereby assumed that each
marker contributes equally to the activity of the mechanism
to which it belongs.
Results
Table 1 shows the characteristics of the individuals with
vascular complications (cases) compared with those with-
out (controls).
Associations between sRAGE and cardiovascular
and microvascular disease
Individuals with CVD had higher levels of sRAGE than
those without CVD: β=0.16 ng/ml (95% CI 0.05–0.26)
(Table 2, model 1; Fig. 1). Adjustments for other risk
factors did not change this difference (model 2).
sRAGE levels (in ng/ml) were also increased across the
levels of severity of albuminuria (β=0.04 [−0.08, 0.16] and
β=0.13 [0.01–0.25]) in individuals with micro- and macro-
albuminuria compared with those with normoalbuminuria,
respectively (p for trend=0.031) and similarly across the
levels of severity of retinopathy (β=0.06 [−0.04, 0.15] and
β=0.12 [0.01–0.22]) in those with non-proliferative and
proliferative compared with those without retinopathy,
respectively (p for trend=0.037; Table 2; model 1; Fig. 1).
These differences were not markedly attenuated after
further adjustments for other risk factors but were no longer
statistically significant (model 2).
Association between sRAGE and markers of endothelial
and renal dysfunction, low-grade inflammation and AGEs
sRAGE was positively and significantly associated with
endothelial dysfunction, low-grade inflammation and AGE
scores, and even more strongly so with levels of eGFR
(Table 3; model 1). Adjustments for other cardiovascular
risk factors did not materially change these associations
(model 2).
Mediating effects of endothelial and renal dysfunction
and low-grade inflammation in the associations
between sRAGE and cardiovascular
and microvascular complications
The differences in sRAGE between individuals with CVD
compared with those without were attenuated after adjust-
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ments for markers of endothelial dysfunction and low-grade
inflammation and more strongly so after adjustments for
eGFR (Table 2, models 3–5 compared with model 2). These
variables explained about 13%, 20% and 33% of the
association between sRAGE levels and the prevalence of
CVD, respectively. All together, these potential mediators
explained about 50% (change of β from 0.15 in model 2 to
0.08 in model 6) of the differences in sRAGE between
individuals with CVD compared with those without.
Endothelial dysfunction, low-grade inflammation and par-
ticularly eGFR also attenuated the differences in sRAGE
levels across the levels of severity of albuminuria and
retinopathy (Table 2, models 3–6).
Additional analyses
In the analyses above (Table 2, model 4), we have
considered eGFR (a marker of kidney dysfunction) as a
potential mediator in the relationship between sRAGE and
vascular complications. However, kidney dysfunction could
also be a confounder in the association between sRAGE
levels and vascular complications, and our analyses cannot
distinguish between these possibilities. Finally, eGFR could
also be a risk marker of vascular complications. When
analysed as such, we observed that individuals with CVD
had lower eGFR than those without (β=−4.66 ml/min [95%
CI −8.75, −0.57], after adjustments for other cardiovascular
risk factors and sRAGE levels). However, the inverse
associations reported between sRAGE and eGFR (Table 3,
models 1 and 2), were not attenuated when further adjusted
for the presence of vascular disease (Table 3, model 3), which
argues against eGFR being a risk marker of vascular disease.
We found a significant effect modification by sex in the
association between sRAGE and CVD (p for sex interac-
tion=0.008), indicating that the association between
sRAGE and CVD was stronger in men (β=0.25 ng/ml
[0.08–0.43]) than in women (β=0.07 ng/ml [−0.07, 0.20]).
However, in both sexes the direction of the association was
the same and the number of cases and controls did not
differ markedly between the two sexes: 55:81 and 61:97 in
men and women, respectively. In addition, no effect
modification by sex was found in any of the other
associations investigated, i.e. in the associations between
plasma sRAGE and microvascular complications and in the
associations between sRAGE and markers of endothelial
and renal dysfunction and inflammation.
We have also explored whether the level of glycaemic
control influenced the associations reported herein. We
found no evidence for effect modification by HbA1c (our
measure of glycaemic control) in the associations exam-
Table 1 Clinical characteristics of the study population (n=477)
Characteristic Vascular complications (n=299) No vascular complications (n=178) p value
Age (years) 41.7 (10.4) 35.9 (8.1) <0.001
Sex, male/female (%) 54/46 46/54 0.072
BMI (kg/m2) 24.9 (3.5) 23.7 (2.6) <0.001
HbA1c (%) 9.0 (1.6) 7.8 (1.3) <0.001
Duration of diabetes (years) 25.2 (9.1) 15.3 (7.0) <0.001
LDL-cholesterol (mmol/l) 3.25 (1.09) 2.87 (0.90) <0.001
HDL-cholesterol (mmol/l) 1.59 (0.42) 1.69 (0.45) 0.022
Triacylglycerol (mmol/l) 1.14 (0.85–1.58) 0.85 (0.66–1.09) <0.001
Smoking: none/moderate/heavy (%) 39/27/34 51/31/18 <0.001
Diastolic BP (mmHg) 75 (12) 73 (11) 0.048
Systolic BP (mmHg) 127 (21) 114 (14) <0.001
Serum creatinine (μmol/l) 76 (68–90) 71 (64–78) <0.001
eGFR (ml min−1 1.73 m−2) 68 (22) 80 (17) <0.001
CVD (%) 38.8 – –
Albuminuria: normo-/micro-/macro- (%) 38.5/24.1/37.5 – –
Retinopathy: none/background/proliferative (%) 11.7/41.1/47.2 – –
CRP (mg/l) 1.30 (0.46–2.80) 0.71 (0.35–1.82) <0.001
IL-6 (pg/ml) 2.13 (1.35–3.94) 1.55 (1.05–2.49) <0.001
TNF-α (pg/ml) 3.17 (2.40–4.41) 2.23 (1.68–2.85) <0.001
sE-selectin (ng/ml) 36 (17) 31 (11) <0.001
sVCAM-1(ng/ml) 437 (147) 379 (104) <0.001
CEL (μmol [mmol lysine]−1) 0.030 (0.012) 0.031 (0.011) 0.896
CML (μmol [mmol lysine]−1) 0.058 (0.020) 0.055 (0.015) 0.097
Pentosidine (nmol [mmol urinary creatinine]−1) 0.46 (0.33–0.67) 0.43 (0.32–0.56) 0.003
Data are means (SD), median (interquartile range) or percentages, as appropriate
CEL, Nɛ -(carboxyethyl)lysine; CML, Nɛ -(carboxymethyl)lysine
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ined, indicating that the (positive) associations between
sRAGE and macro- and microvascular complications as
well as between sRAGE levels and markers of endothelial
and renal dysfunction and inflammation were similar for
individuals with better or poorer glycaemic control.
Discussion
The main finding of this study is that sRAGE levels are
positively associated with CVD in type 1 diabetes. This
association was independent of other ‘traditional’ cardio-
vascular risk factors, but could be partially explained by
endothelial and renal dysfunction and low-grade inflamma-
tion. Although sRAGE has been investigated in several
Table 2 Associations between levels of sRAGE and CVD, albuminuria and retinopathy
Model CVDa Albuminuriab Retinopathyc
βd 95% CI p value Microalbuminuria Macroalbuminuria p value
for trend
Non-proliferative Proliferative p value
for trend
βe 95% CI βe 95% CI βf 95% CI βf 95% CI
1 0.16 0.05, 0.26 0.005 0.04 −0.08, 0.16 0.13 0.01, 0.25 0.031 0.06 −0.04, 0.15 0.12 0.01, 0.22 0.037
2 0.15 0.04, 0.27 0.007 0.04 −0.08, 0.16 0.11 −0.02, 0.24 0.087 0.07 −0.03, 0.17 0.11 0.00, 0.22 0.057
3 0.13 0.02, 0.24 0.017 0.01 −0.11, 0.13 0.06 −0.07, 0.18 0.350 0.05 −0.05, 0.14 0.09 −0.02, 0.20 0.106
4 0.10 −0.01, 0.20 0.074 −0.01 −0.13, 0.10 −0.03 −0.15, 0.10 0.670 0.04 −0.06, 0.13 −0.01 −0.12, 0.10 0.815
5 0.12 0.01, 0.23 0.033 0.00 −0.12, 0.13 0.06 −0.07, 0.19 0.351 0.03 −0.07, 0.13 0.06 −0.05, 0.17 0.249
6 0.08 −0.03, 0.18 0.147 −0.04 −0.15, 0.08 −0.06 −0.18, 0.07 0.381 0.01 −0.08, 0.11 −0.02 −0.13, 0.09 0.684
a Individuals without CVD but with microvascular complications (n=183) were excluded from these analyses
b Individuals with normoalbuminuria but with CVD or retinopathy (n=115) were excluded from these analyses
c Individuals without retinopathy but with CVD or albuminuria (n=35) were excluded from these analyses
d–f Regression coefficients (β) indicate difference in sRAGE levels (in ng/ml) between: d individuals with (n=116) vs without CVD (n=178);
e individuals with micro- (n=72) or macroalbuminuria (n=112) vs those with normoalbuminuria (reference group; n=178); f individuals with non-
proliferative (n=123) or proliferative retinopathy (n=141) vs those without retinopathy (reference group; n=178)
Model 1, adjusted for age, sex, duration of diabetes and HbA1c
Model 2, model 1+adjustments for other cardiovascular risk factors (i.e. BMI, triacylglycerols, HDL- and LDL-cholesterol, smoking and systolic BP)
Model 3, model 2+endothelial dysfunction z score
Model 4, model 2+eGFR
Model 5, model 2+inflammation z score







































Fig. 1 sRAGE levels according to the presence of CVD and the
presence and severity of albuminuria and retinopathy. Bars are means
adjusted for age, sex, duration of diabetes and HbA1c; error bars
indicate SEs of the means. Individuals with CVD (n=116) had higher
levels of sRAGE than those without CVD or any microvascular
complications (n=178): p=0.005. sRAGE levels were higher in the
presence and across the levels of severity of albuminuria (p value for
trend=0.031) and retinopathy (p value for trend=0.037)
Table 3 Associations between sRAGE levels and markers of
endothelial and renal dysfunction, low-grade inflammation and AGEs
Dependent variables Model βa 95% CI p value
Endothelial dysfunction
z score
1 0.18 0.12, 0.24 <0.001
2 0.17 0.11, 0.23 <0.001
eGFR 1 −0.30 −0.38, −0.23 <0.001
2 −0.26 −0.33, −0.19 <0.001
3 −0.25 −0.32, −0.18 <0.001
Inflammation z score 1 0.15 0.09, 0.21 <0.001
2 0.14 0.09, 0.20 <0.001
AGE z score 1 0.21 0.15, 0.27 <0.001
2 0.20 0.14, 0.25 <0.001
a β, standardised regression coefficient: indicates increase (in SDs) of
the dependent variable per 1 SD increase in sRAGE levels
Model 1, adjusted for age, sex, duration of diabetes and HbA1c
Model 2, model 1 + adjustments for other cardiovascular risk factors
(i.e. BMI, triacylglycerol, HDL- and LDL-cholesterol, smoking and
systolic BP
Model 3, model 2 + adjustment for the presence of vascular
complications
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studies, findings have been scattered. This is the first study
that has investigated the associations between sRAGE and
macro- and microvascular complications in a large sample
of individuals with type 1 diabetes, and has also addressed
potential mechanisms that could explain the observed
associations.
Human endothelial cells express at least three RAGE
variants [4]. The first one is the full-length RAGE, the
second, the N-terminally truncated variant with a still
unknown function, and the third, the C-terminally truncated
soluble form. This naturally occurring form of sRAGE, as
well as artificially produced sRAGE, can potentially bind to
an AGE ligand thereby acting as a decoy, preventing AGE–
RAGE interaction and activation [4]. This could thus
explain any inverse association observed between sRAGE
and vascular complications. However, although sRAGE has
been an interesting subject of investigation under this
suspected decoy function, it is very unlikely that sRAGE
can act as such (i.e. by capturing and eliminating AGEs)
because the sRAGE concentrations found in plasma are
approximately 1,000 times lower than needed for efficient
binding and elimination of AGEs [14, 16]. The increased
levels of sRAGE in individuals with CVD and across levels
of severity of albuminuria and retinopathy, as well as the
positive association between sRAGE and AGEs reported
herein thus seem not to sustain such a decoy function.
The observed positive association between sRAGE and
CVD is in agreement with earlier observations in type 2
diabetes [15] and heart failure patients [42], although
opposite findings have been reported in non-diabetic men
[43]. In addition, esRAGE and sRAGE levels were
inversely associated with carotid IMT [18, 20] and its
progression [21] in individuals with type 1 diabetes;
because carotid IMT is considered as a valid marker of
atherosclerosis, which is a strong underlying cause of CVD,
these findings seem to contradict the ones reported herein.
However, because associations with clinical cardiovascular
events were not reported in those studies and we have not
measured carotid IMT, we cannot fully judge these apparent
discrepancies. Interestingly, in another study in type 2
diabetes both esRAGE and sRAGE were positively, not
inversely, associated with carotid IMT, although not
significantly so [16].
sRAGE levels were also positively associated with
microvascular complications, although these were not
independent of other risk factors in the present study.
Positive associations between sRAGE levels and albumin-
uria have been consistently reported previously [13, 16,
44]. It is important to note that the only study where
associations between both esRAGE and sRAGE on the one
hand and UAE on the other were investigated in the same
population (type 2 diabetes), both soluble forms of RAGE
were positively associated with UAE, but sRAGE more
strongly (and significantly so) than esRAGE [16]. The
increased levels of sRAGE across levels of severity of
retinopathy observed in our study were also in line with a
previous study [17]. In contrast, individuals with diabetic
retinopathy were characterised by lower esRAGE levels
compared with individuals without retinopathy [19].
The reasons for the contradictory findings reported
above are not clear but may be explained by differences
in the study population (i.e. diabetes vs no diabetes) and/or
by the fact that different variants of sRAGE are detected by
different assays used in different studies, namely the total
pool of sRAGE by the Quantikine sRAGE ELISA kit
(R&D Systems, Minneapolis, USA) [13–17] or specifically
esRAGE by the B-Bridge International esRAGE ELISA kit
(Daiichi Fine Chemicals, Takaoka, Japan) [16, 18, 19]. This
is also supported by the increased sRAGE [13, 15, 17, 20],
but decreased esRAGE levels [18–20] reported in individ-
uals with diabetes compared with controls. These two
assays measure different pools of sRAGE and different
variants of sRAGE may have different functions and
therefore they are not inter-exchangeable. Indeed, the
regulatory mechanisms for proteolytic shedding of cell-
bound RAGE to generate sRAGE and for alternative
splicing to generate esRAGE are still unclear. Recently,
new splice variants have been discovered [6] and fur-
ther studies are necessary to establish which variants of
sRAGE are measured by these assays and whether
different soluble forms of RAGE have different (patho)
physiological functions.
We, as others, have found positive associations between
sRAGE and markers of endothelial dysfunction and low-
grade inflammation [14, 45]. The current view is that the
activation of RAGE, a 55 kDa protein and member of the
immunoglobulin superfamily of cell-surface receptors,
through ligand binding activates the endothelial cell and
triggers multiple signalling cascades [8, 9]. This results in
activation and translocation of nuclear transcription factors
and transcription of the target genes, including those for
VCAM-1 [9], E-selectin [10] and proinflammatory cyto-
kines [11]. AGEs are positive regulators of the cellular
RAGE expression [46], and an increased formation of
AGEs enhanced the expression and secretion of the soluble
forms of RAGE [47, 48]. In addition, the positive
association between sRAGE and AGEs observed in this
and other studies [13, 14] supports the view that sRAGE
could be a reflection of RAGE, and that activation of the
AGE–RAGE axis can lead to increased endothelial dys-
function and low-grade inflammation, and subsequently to
an increased risk of cardiovascular complications in type 1
diabetes.
We have shown that sRAGE is positively and indepen-
dently associated with renal dysfunction, defined by lower
eGFR. This is in line with a recent study in which sRAGE
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(and also esRAGE) were inversely associated with current
and follow-up levels of eGFR in a large population of
elderly women [49]. In addition, it has been shown that the
activation of the AGE–RAGE axis could lead to glomer-
ulosclerosis and glomerular hyperpermeability through the
upregulation of vascular endothelial growth factor and/or
transforming growth factor-β [12]. We have also shown
that renal dysfunction mediated the associations between
sRAGE levels on the one hand and CVD or microvascular
complications on the other. Although there is some evidence
to support the assumption of renal dysfunction being a
mediator in the causal pathway between sRAGE levels (as a
reflection of the activity of the AGE–RAGE axis) and
vascular complications, we cannot neglect the possibility of
renal dysfunction being a confounder in these associations.
It is unclear why the relationship between sRAGE levels
and CVD observed in the present study was stronger in
men than in women. sRAGE levels did not differ between
the two sexes and no significant effect modification by sex
was found in any of the other associations investigated.
Therefore, we cannot discard the possibility that this finding
was due to chance. In addition, differences (if any) between
sexes in the association between sRAGE and vascular
complications have not been reported before. Interestingly,
women with polycystic ovary syndrome were found to have
higher levels of serum AGEs and RAGE expression on
circulating monocytes than healthy controls, and these
differences may be partly explained by their elevated levels
of testosterone [50]. Altogether, these findings suggest that
the role of sex hormones in the associations between
plasma sRAGE and CVD may need to be further explored.
There are limitations to our study. First, we cannot
establish whether the associations are causal due to the
cross-sectional design of the study. Further follow-up data
on these or other patient groups would, of course, be
invaluable, in testing whether our findings are probably due
to causal relationships. However, no longitudinal data of
this type exist in large groups of individuals with type 1
diabetes at the time, and therefore this cross-sectional study
may serve as a reasonable starting point to further explore
these associations. Second, our findings are limited to type
1 diabetic individuals and extrapolations to non-diabetic
individuals may need caution. Third, although we mini-
mised the influence of confounding in the associations
observed by adjustments for many possible confounders,
interference by factors we did not measure cannot be ruled
out. Fourth, the levels of the mediators investigated were
only measured once, which might have diluted the
associations we found. However, we combined different
markers of the potential mediators in z scores to yield more
robust scores. Finally, there may be some concerns with
regard to the effects of storage on plasma sRAGE levels.
Such effects, if any (e.g. autoglycosylation) are unknown.
However, because the storing time and conditions (−80°C)
were similar to all samples, any bias that may have
occurred is likely to have been non-differential and
therefore did not affect our overall findings.
In conclusion, in this study of individuals with type 1
diabetes, sRAGE was found to be significantly associated
with CVD and this was independent of other cardiovascular
risk factors. Endothelial and renal dysfunction and low-
grade inflammation explained about 50% of this associa-
tion, suggesting that sRAGE levels as a reflection of RAGE
lead to greater prevalence of CVD through increased
endothelial and renal dysfunction and low-grade inflamma-
tion. Nevertheless, the precise role of sRAGE in the
pathophysiology of diabetes and vascular complications
needs to be explored further in prospective studies.
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